Beta-blockers in heart failure

Newson, Louise
February 2007
GP: General Practitioner;2/2/2007, p45
The article focuses on the use of beta-blockers in heart failure (HF). The author thinks that HF is a common but poorly managed condition. In the Cardiac Insufficiency Bisoprolol Trial II, the Carvedilol Prospective Randomised Cumulative Survival Study (COPERNICUS) and the Metoprolol Randomised Intervention Trial in Congestive Heart Failure, have shown that beta-blocker treatment with bisoprolol, carvedilol and metoprolol reduces mortality in advanced HF patients.


Related Articles

  • Beta-blockers in severe heart failure.  // Caribbean Health;Dec2001, Vol. 4 Issue 6, p19 

    The article discusses the clinical concept of beta-blockers. These benefit patients with mild or moderate heart failure. However, their effects on patients with severe heart failure are uncertain. With this, two large international trials have produced apparently conflicting results. The...

  • Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure. Jens Rosenberg; Finn Gustafsson; Willem Remme; Günter Riegger; Per Hildebrandt // Cardiovascular Drugs & Therapy;Aug2008, Vol. 22 Issue 4, p305 

    Abstract Introduction  The long-term effect of beta-blockade on the plasma levels of natriuretic peptides BNP and its N-terminal counterpart, NT-proBNP, as risk markers in heart failure (HF) is obscure. Methods  Stable systolic HF patients from the CARMEN study...

  • Should We Restrict Sodium Intake in Compensated Heart Failure? Corlan, Ileana // Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 2, p139 

    The article discusses the significance of sodium intake of patients with compensated heart failure. One of the main dietary recommendations in patients with congestive heart failure is sodium intake restriction, based on the well known kidney inability to excrete excess sodium in untreated heart...

  • Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. Al-Gobari, Muaamar; Khatib, Chadia El; Pillon, François; Gueyffier, François // BMC Cardiovascular Disorders;2013, Vol. 13 Issue 1, p1 

    Background: In many studies, beta-blockers have been shown to decrease sudden cardiac death (SCD) in heart failure patients; other studies reported mixed results. Recently, several large randomized control trials of beta blockers have been carried out. It became necessary to conduct a systematic...

  • Hypertension: Which drugs to choose for patients with cardiovascular disease. Wexler, Randy; Feldman, David // Journal of Family Practice;Apr2006, Vol. 55 Issue 4, p291 

    The article presents recommendations for treating patients with cardiovascular diseases such as heart failure, coronary artery disease and stroke. Hypertension is linked to heart failure cases, heart attacks and first-time strokes. A study was conducted that aims to identify a drug that will...

  • Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or ... Waagstein, F.; Str�mblad, O.; Andersson, B.; B�hm, M.; Darius, M.; Delius, W.; Goss, F.; Osterziel, K.J.; Sigmund, M.; Trenkwalder, S.-P.; Wahlqvist, I. // European Journal of Heart Failure;Oct2003, Vol. 5 Issue 5, p679 

    Background: the effects of long-term administration of �-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart...

  • What doesn't kill you. Martindale, Diane // New Scientist;10/25/2003, Vol. 180 Issue 2418, p38 

    Dishing out drugs that make your symptoms worse seems like a rash, even dangerous way to treat patients. Miracle workers rarely come back for an encore, but in the world of heart medicine one little miracle is bucking the trend. Beta blockers were invented in 1964 and quickly became the most...

  • PII-1. Cheang, K. I.; Vardeny, O.; Zebrack, J. S.; Munger, M. A.; Gilbert, E. M. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP35 

    Background: β2-adrenergic receptor (ADRB2) polymorphisms affect β2-mediated glucose production by terbutaline. Whether beta-blockers' effects on β2-mediated glucose production are affected by ADRB2 polymorphisms is unknown. This study determines the effect of ADRB2 Arg16Gly and Glu27Gln...

  • News in brief...  // PharmacoEconomics & Outcomes News;1/17/2004, Issue 444, p6 

    Discusses research being done on the use of beta-blocker in patients with chronic heart failure. Reference to a study by R. Gupta et al, published in the January 2004 issue of the "American Heart Journal"; Percentage of the patients who were receiving beta-blocker; Age range of the patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics